Formulation Development
ArriVent BioPharma Enters Exclusive License With Lepu Biopharma for an Antibody Drug Conjugate for the Treatment of Gastrointestinal Cancers
ArriVent BioPharma, Inc. recently announced it has entered into an exclusive license agreement with Lepu Biopharma Co., Ltd (Stock Code: 02157.HK) for MRG007, an antibody-drug…
IMMvention Therapeutix Enters Strategic Collaboration With Novo Nordisk to Develop Oral Therapies
IMMvention Therapeutix, Inc. recently announced a strategic collaboration and license agreement with Novo Nordisk A/S to co-develop oral therapies for sickle cell disease (SCD) and…
Silo Pharma Advances Intellectual Property Portfolio With Provisional Patent Filing for PTSD Treatment
Silo Pharma, Inc. recently announced the filing of a provisional patent application with the U.S. Patent and Trademark Office (USPTO). This application, focused on its…
Artax Biopharma Achieves Clinical Validation of First-in-Class Oral Nck Modulator for Autoimmune Disease in Phase 2a Study
Artax Biopharma, Inc. recently announced achievement of clinical validation through its Phase 2a clinical trial in psoriasis with fully proprietary oral agent AX-158. These results…
Altamira Therapeutics Announces Collaboration on Radiopharmaceutical Targeting Strategies
Altamira Therapeutics Ltd. recently announced it has entered into a collaboration agreement with a company in the radiopharmaceutical sector to evaluate the use of the…
Bluejay Therapeutics Receives FDA Breakthrough Therapy Designation for Brelovitug for the Treatment of Chronic Hepatitis Delta
Bluejay Therapeutics recently announced its lead product candidate brelovitug (also known as BJT-778) has received U.S. Food and Drug Administration (FDA) Breakthrough Therapy designation for…
Coya Therapeutics Announces Pipeline Expansion - COYA 303: COYA 301 in Combination With GLP-1 Receptor Agonist for the Treatment of Inflammatory Diseases
Coya Therapeutics, Inc. recently announced the expansion of its investigational pipeline and advancement of COYA 303 for the treatment of inflammatory diseases. Sustained inflammatory responses…
Shuttle Pharma Reaches Milestone in Patient Enrollment for Phase 2 Trial of Ropidoxuridine for Treatment of Patients With Glioblastoma
Shuttle Pharmaceuticals Holdings, Inc. recently announced it has achieved 25% enrollment in the initial randomized portion of its Phase 2 Clinical Trial of Ropidoxuridine for…
Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 With Trabectedin in Certain Sarcomas
Sonnet BioTherapeutics Holdings, Inc. recently announced an expansion of its Phase 1 SB101 clinical study of SON-1010 (IL12-FHAB) in adult patients with advanced solid tumors…
Micron Biomedical Extends Series A Financing to 33+ Million to Accelerate Commercialization of Needle-Free Therapeutics & Vaccines
Micron Biomedical, a life science company developing the world’s first needle-free technology for drugs and vaccines that is based on dissolvable microarrays, today announced it…
ReciBioPharm Secures Significant Grant to Advance RNA Manufacturing
ReciBioPharm, a division of Recipharm and a leading Contract Development and Manufacturing Organization (CDMO), has been awarded a 3-year grant from the Bill & Melinda…
Palisade Bio Completes All Five SAD Cohorts & Advances to MAD Cohorts of Phase 1a/b Study of PALI-2108 for Treatment of Ulcerative Colitis
Palisade Bio, Inc recently announced the completion of all five planned Single Ascending Dose (SAD) cohorts and the commencement of the Multiple Ascending Dose (MAD)…
Nipro & Nemera Prove Compatibility of Unit-Dose Microvials & UniSpray
Nipro PharmaPackaging and Nemera recently announced the successful compatibility testing of Nemera’s UniSpray and Nipro’s unit-dos microvials. This collaboration aims to accelerate the time to…
Lyndra Therapeutics Announces Strategic Clinical Research & Commercial Manufacturing Services Collaboration With Thermo Fisher Scientific
Lyndra Therapeutics recently announced a strategic collaboration with Thermo Fisher Scientific Inc., the world leader in serving science, in which Thermo Fisher will provide global…
Attralus Announces Enrollment of First Patient in Phase 3 Trial for the Pan-Amyloid Diagnostic 124I-evuzamitide (AT-01) for Cardiac Amyloidosis
Attralus, Inc. recently announced the enrollment of the first patient in the Research with 124I-EVuzamitide to Elucidate Cardiac AmyLoidosis (REVEAL) study – A Phase 3…
Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase 2b/3 Data
Anavex Life Sciences Corp. recently announced the The Journal of Prevention of Alzheimer’s Disease (JPAD) has published peer-reviewed detailed results from the Phase 2b/3 study…
Abzena Strengthens Board With Appointment of Biopharma Industry Leader, Dr. Moncef Slaoui
Abzena, the leading end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, has today announced the appointment of Moncef Slaoui, PhD, to its Board…
Iconovo & Lonza to Collaborate on the Formulation Development of an Intranasal Biologic
Iconovo AB, a leader in the development of inhalable drugs based on proprietary inhalers and dry powder formulations, today announced that Iconovo and Lonza initiated…
Alcami Announces CEO Transition
[caption id="attachment_144551" align="alignleft" width="153"] Patrick Walsh[/caption] Alcami Corporation, a leading contract development and manufacturing organization (CDMO), recently announced the resignation of Bill Humphries. Alcami’s Board…
BioMed X Institute Launches New Collaboration With Daiichi Sankyo in Cancer Therapy
BioMed X recently announced the launch of a new collaboration with Daiichi Sankyo Co., Ltd., a global pharmaceutical company headquartered in Japan. This collaboration marks the…
